Targeted Therapies for Previously “Undruggable” KRAS-Mutated Non–Small Cell Lung Cancer: A Review of Sotorasib and Adagrasib

Objective: To evaluate the safety and efficacy of the novel KRAS-targeting agents, sotorasib and adagrasib, in treating KRAS G12C-mutated non–small cell lung cancer (NSCLC). Data Sources: A comprehensive English-based literature search of PubMed and Clinicaltrials.gov between January 2000 and July 2...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of Pharmacotherapy 2024-06, Vol.58 (6), p.622-635
Hauptverfasser:	Mausey, Natalie, Halford, Zachery
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - pharmacology Antineoplastic Agents - therapeutic use Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - genetics Humans Lung Neoplasms - drug therapy Lung Neoplasms - genetics Molecular Targeted Therapy Mutation Piperazines Proto-Oncogene Proteins p21(ras) - antagonists & inhibitors Proto-Oncogene Proteins p21(ras) - genetics Pyridines - adverse effects Pyridines - pharmacology Pyridines - therapeutic use Pyrimidines - pharmacology Pyrimidines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!